Autophagy suppression promotes apoptotic cell death in response to inhibition of the PI3K—mTOR pathway in pancreatic adenocarcinoma
Identifieur interne : 001582 ( Main/Merge ); précédent : 001581; suivant : 001583Autophagy suppression promotes apoptotic cell death in response to inhibition of the PI3K—mTOR pathway in pancreatic adenocarcinoma
Auteurs : Olga K. Mirzoeva [États-Unis] ; Byron Hann [États-Unis] ; Yun K. Hom [États-Unis] ; Jayanta Debnath [États-Unis] ; Dana Aftab [États-Unis] ; Kevan Shokat [États-Unis] ; W. Michael Korn [États-Unis]Source :
- Journal of Molecular Medicine [ 0946-2716 ] ; 2011-09-01.
English descriptors
- KwdEn :
Abstract
Abstract: Targeting of pathways downstream of RAS represents a promising therapeutic strategy for pancreatic cancer, the fourth leading cause of cancer-related death in the USA, since activation of the Raf-MEK-ERK and PI3K-AKT pathways is found frequently in this disease and is associated with poor prognosis. Taking advantage of a panel of human PDAC cell lines and specific inhibitors of PI3K and/or mTOR, we systematically address the question whether dual-targeted inhibition of the PI3K and mTOR pathways offers advantages over single-targeted inhibition of PI3K in PDAC. We observe greater overall susceptibility of cell lines to dual inhibition compared to targeting PI3K alone. However, we find that dual inhibition of PI3K and mTOR induces autophagy to a greater extent than inhibition of each target alone. In agreement with this, we show that combined administration of PI3K/mTOR and autophagy inhibitors results in increased anti-tumor activity in vitro and in vivo in models of pancreatic adenocarcinoma. XL765, a PI3K/mTOR inhibitor used in our in vivo studies, is currently undergoing clinical evaluation in a variety of cancer types, while the autophagy inhibitor chloroquine is a widely used anti-malaria compound. Thus, our studies provide rationale for clinical development of combinations of these compounds for the treatment of pancreatic adenocarcinoma.
Url:
DOI: 10.1007/s00109-011-0774-y
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000665
- to stream Istex, to step Curation: 000665
- to stream Istex, to step Checkpoint: 000556
Links to Exploration step
ISTEX:FFEEE7417834D5D772E6CBCD2EC1C29E357A07EFLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Autophagy suppression promotes apoptotic cell death in response to inhibition of the PI3K—mTOR pathway in pancreatic adenocarcinoma</title>
<author><name sortKey="Mirzoeva, Olga K" sort="Mirzoeva, Olga K" uniqKey="Mirzoeva O" first="Olga K." last="Mirzoeva">Olga K. Mirzoeva</name>
</author>
<author><name sortKey="Hann, Byron" sort="Hann, Byron" uniqKey="Hann B" first="Byron" last="Hann">Byron Hann</name>
</author>
<author><name sortKey="Hom, Yun K" sort="Hom, Yun K" uniqKey="Hom Y" first="Yun K." last="Hom">Yun K. Hom</name>
</author>
<author><name sortKey="Debnath, Jayanta" sort="Debnath, Jayanta" uniqKey="Debnath J" first="Jayanta" last="Debnath">Jayanta Debnath</name>
</author>
<author><name sortKey="Aftab, Dana" sort="Aftab, Dana" uniqKey="Aftab D" first="Dana" last="Aftab">Dana Aftab</name>
</author>
<author><name sortKey="Shokat, Kevan" sort="Shokat, Kevan" uniqKey="Shokat K" first="Kevan" last="Shokat">Kevan Shokat</name>
</author>
<author><name sortKey="Korn, W Michael" sort="Korn, W Michael" uniqKey="Korn W" first="W. Michael" last="Korn">W. Michael Korn</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:FFEEE7417834D5D772E6CBCD2EC1C29E357A07EF</idno>
<date when="2011" year="2011">2011</date>
<idno type="doi">10.1007/s00109-011-0774-y</idno>
<idno type="url">https://api.istex.fr/ark:/67375/VQC-C97Z80MR-P/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000665</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000665</idno>
<idno type="wicri:Area/Istex/Curation">000665</idno>
<idno type="wicri:Area/Istex/Checkpoint">000556</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000556</idno>
<idno type="wicri:doubleKey">0946-2716:2011:Mirzoeva O:autophagy:suppression:promotes</idno>
<idno type="wicri:Area/Main/Merge">001582</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Autophagy suppression promotes apoptotic cell death in response to inhibition of the PI3K—mTOR pathway in pancreatic adenocarcinoma</title>
<author><name sortKey="Mirzoeva, Olga K" sort="Mirzoeva, Olga K" uniqKey="Mirzoeva O" first="Olga K." last="Mirzoeva">Olga K. Mirzoeva</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Divisions of Gastroenterology and Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hann, Byron" sort="Hann, Byron" uniqKey="Hann B" first="Byron" last="Hann">Byron Hann</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hom, Yun K" sort="Hom, Yun K" uniqKey="Hom Y" first="Yun K." last="Hom">Yun K. Hom</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Debnath, Jayanta" sort="Debnath, Jayanta" uniqKey="Debnath J" first="Jayanta" last="Debnath">Jayanta Debnath</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pathology, University of California San Francisco, San Francisco, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Aftab, Dana" sort="Aftab, Dana" uniqKey="Aftab D" first="Dana" last="Aftab">Dana Aftab</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Exelixis, Inc, South San Francisco, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Shokat, Kevan" sort="Shokat, Kevan" uniqKey="Shokat K" first="Kevan" last="Shokat">Kevan Shokat</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Korn, W Michael" sort="Korn, W Michael" uniqKey="Korn W" first="W. Michael" last="Korn">W. Michael Korn</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Divisions of Gastroenterology and Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>UCSF Divisions of Gastroenterology and Hematology/Oncology, Department of Medicine, Helen Diller Family Comprehensive Cancer Center, 2340 Sutter St., Box 1387, 94115, San Francisco, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><country wicri:rule="url">États-Unis</country>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Journal of Molecular Medicine</title>
<title level="j" type="abbrev">J Mol Med</title>
<idno type="ISSN">0946-2716</idno>
<idno type="eISSN">1432-1440</idno>
<imprint><publisher>Springer-Verlag</publisher>
<pubPlace>Berlin/Heidelberg</pubPlace>
<date type="published" when="2011-09-01">2011-09-01</date>
<biblScope unit="volume">89</biblScope>
<biblScope unit="issue">9</biblScope>
<biblScope unit="page" from="877">877</biblScope>
<biblScope unit="page" to="889">889</biblScope>
</imprint>
<idno type="ISSN">0946-2716</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0946-2716</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Apoptosis</term>
<term>Autophagy</term>
<term>Cancer signal transduction</term>
<term>Chloroquine</term>
<term>EGFR pathway</term>
<term>PI3K</term>
<term>Pancreatic adenocarcinoma</term>
<term>mTOR</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Abstract: Targeting of pathways downstream of RAS represents a promising therapeutic strategy for pancreatic cancer, the fourth leading cause of cancer-related death in the USA, since activation of the Raf-MEK-ERK and PI3K-AKT pathways is found frequently in this disease and is associated with poor prognosis. Taking advantage of a panel of human PDAC cell lines and specific inhibitors of PI3K and/or mTOR, we systematically address the question whether dual-targeted inhibition of the PI3K and mTOR pathways offers advantages over single-targeted inhibition of PI3K in PDAC. We observe greater overall susceptibility of cell lines to dual inhibition compared to targeting PI3K alone. However, we find that dual inhibition of PI3K and mTOR induces autophagy to a greater extent than inhibition of each target alone. In agreement with this, we show that combined administration of PI3K/mTOR and autophagy inhibitors results in increased anti-tumor activity in vitro and in vivo in models of pancreatic adenocarcinoma. XL765, a PI3K/mTOR inhibitor used in our in vivo studies, is currently undergoing clinical evaluation in a variety of cancer types, while the autophagy inhibitor chloroquine is a widely used anti-malaria compound. Thus, our studies provide rationale for clinical development of combinations of these compounds for the treatment of pancreatic adenocarcinoma.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001582 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 001582 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= ChloroquineV1 |flux= Main |étape= Merge |type= RBID |clé= ISTEX:FFEEE7417834D5D772E6CBCD2EC1C29E357A07EF |texte= Autophagy suppression promotes apoptotic cell death in response to inhibition of the PI3K—mTOR pathway in pancreatic adenocarcinoma }}
This area was generated with Dilib version V0.6.33. |